SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: E.J. Neitz Jr who wrote (6406)6/3/1998 1:29:00 PM
From: aknahow  Respond to of 17367
 
Ed, thanks. I enjoyed the article as you knew I would.

Am using Net Minder to monitor XOMA web. Just signed up with option that sends me an e-mail of the change. Will see how it works and probably add some other sites.

netmind.com



To: E.J. Neitz Jr who wrote (6406)6/4/1998 1:05:00 AM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Little things mean a lot! Or why I like XOMA. From a series of lectures, and this specific one on antibiotic resistance comes the following statement:

Surprisingly,
Streptococcus pyogenes (Group A strep) have never fully developed resistance to penicillin and it remains a reasonable
choice antibiotic for many types of streptococcal infections. Interestingly, penicillin has never been effective against
most Gram-negative pathogens (e.g. Salmonella, Shigella, Bordetella pertussis, Yersinia pestis, Pseudomonas) with the
notable exception of Neisseria gonorrhoeae. Gram-negative bacteria are inherently resistant to penicillin because their
vulnerable cell wall is protected by an outer membrane that prevents permeation of the penicillin molecule.

Certainally makes me believe BPI will have a role in dealing with these bacteria!!!

Entire series is at:

bact.wisc.edu

Recomend Pseudomonas Aeruginosa lecture. XOMA annual report Fig 3a with caption states "It is also the most common multi-drug resistant pathogen in cystic fibrosis patients"